Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis

Clinical Microbiology and Infection

Volumn 17, Issue 6, 2011, Pages 815-820

  Borrell, S ^a,b   Gagneux, S ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antimicrobial; Diversity; Genotyping; Lineage; Microbe; Mycobacteria

Indexed keywords

ARTICLE; DNA SEQUENCE; EPISTASIS; EVOLUTION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; MICROBIAL DIVERSITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

CORYNEBACTERINEAE; MYCOBACTERIUM TUBERCULOSIS;

EID: 79959288418     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03556.x     Document Type: Article

References (61)

1. WHO. Global tuberculosis control - surveillance, planning, financing. Geneva, Switzerland: WHO, 2010.
2. Gandhi NR, Nunn P, Dheda K et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-1843.
3. Comas I, Gagneux S. The past and future of tuberculosis research. PLoS Pathog 2009; 5: e1000600.
4. Achtman M. Evolution, population structure, and phylogeography of genetically monomorphic bacterial pathogens. Annu Rev Microbiol 2008; 62: 53-70.
5. Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 2007; 7: 328-337.
6. Gagneux S, Deriemer K, Van T et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2006; 103: 2869-2873.
7. Brosch R, Gordon SV, Marmiesse M et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci U S A 2002; 99: 3684-3689.
8. Mostowy S, Cousins D, Brinkman J, Aranaz A, Behr MA. Genomic deletions suggest a phylogeny for the Mycobacterium tuberculosis complex. J Infect Dis 2002; 186: 74-80.
9. Mostowy S, Onipede A, Gagneux S et al. Genomic analysis distinguishes Mycobacterium africanum. J Clin Microbiol 2004; 42: 3594-3599.
10. Nguyen D, Brassard P, Menzies D et al. Genomic characterization of an endemic Mycobacterium tuberculosis strain: evolutionary and epidemiologic implications. J Clin Microbiol 2004; 42: 2573-2580.
11. Kato-Maeda M, Rhee JT, Gingeras TR et al. Comparing genomes within the species Mycobacterium tuberculosis. Genome Res 2001; 11: 547-554.
12. Domenech P, Kolly GS, Leon-Solis L, Fallow A, Reed MB. A massive gene duplication event amongst clinical isolates of the Mycobacterium tuberculosis W/Beijing family. J Bacteriol 2010; 192: 4562-4570.
13. Tsolaki AG, Hirsh AE, DeRiemer K et al. Functional and evolutionary genomics of Mycobacterium tuberculosis: insights from genomic deletions in 100 strains. Proc Natl Acad Sci U S A 2004; 101: 4865-4870.
14. Baker L, Brown T, Maiden MC, Drobniewski F. Silent nucleotide polymorphisms and a phylogeny for Mycobacterium tuberculosis. Emerg Infect Dis 2004; 10: 1568-1577.
15. Filliol I, Motiwala AS, Cavatore M et al. Global phylogeny of Mycobacterium tuberculosis based on single nucleotide polymorphism (SNP) analysis: insights into tuberculosis evolution, phylogenetic accuracy of other DNA fingerprinting systems, and recommendations for a minimal standard SNP set. J Bacteriol 2006; 188: 759-772.
16. Gutacker MM, Mathema B, Soini H et al. Single-nucleotide polymorphism-based population genetic analysis of Mycobacterium tuberculosis strains from 4 geographic sites. J Infect Dis 2006; 193: 121-128.
17. Reed MB, Pichler VK, McIntosh F et al. Major Mycobacterium tuberculosis lineages associate with patient country of origin. J Clin Microbiol 2009; 47: 1119-1128.
18. Hirsh AE, Tsolaki AG, DeRiemer K, Feldman MW, Small PM. Stable association between strains of Mycobacterium tuberculosis and their human host populations. Proc Natl Acad Sci U S A 2004; 101: 4871-4876.
19. Hershberg R, Lipatov M, Small PM et al. High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol 2008; 6: e311.
20. Smith NH, Hewinson RG, Kremer K, Brosch R, Gordon SV. Myths and misconceptions: the origin and evolution of Mycobacterium tuberculosis. Nat Rev Microbiol 2009; 7: 537-544.
21. Smith NH, Kremer K, Inwald J et al. Ecotypes of the Mycobacterium tuberculosis complex. J Theor Biol 2005; 239: 220-225.
22. Comas I, Chakravartti J, Small PM et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 2010; 42: 498-503.
23. de Jong BC, Antonio M, Gagneux S. Mycobacterium africanum- review of an important cause of human tuberculosis in West Africa. PLoS Negl Trop Dis 2010; 4: e744.
24. Fleischmann RD, Alland D, Eisen JA et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 2002; 184: 5479-5490.
25. Coscolla M, Gagneux S. Does M. tuberculosis genomic diversity explain disease diversity? Drug Discov Today Dis Mech 2010; 7: e43-e59.
26. Comas I, Homolka S, Niemann S, Gagneux S. Genotyping of genetically monomorphic bacteria: DNA sequencing in Mycobacterium tuberculosis highlights the limitations of current methodologies. PLoS ONE 2009; 4: e7815.
27. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1456-1466.
28. Dos Vultos T, Mestre O, Rauzier J et al. Evolution and diversity of clonal bacteria: the paradigm of Mycobacterium tuberculosis. PLoS ONE 2008; 3: e1538.
29. Werngren J, Hoffner SE. Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J Clin Microbiol 2003; 41: 1520-1524.
30. Velayati AA, Masjedi MR, Farnia P et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009; 136: 420-425.
31. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79: 3-29.
32. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3: 432-442.
33. Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 2004; 10: 1117-1121.
34. Blower SM, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004; 10: 1111-1116.
35. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002; 295: 2042-2046.
36. Andersson DI, Levin BR. The biological cost of antibiotic resistance. Curr Opin Microbiol 1999; 2: 489-493.
37. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312: 1944-1946.
38. Billington OJ, McHugh TD, Gillespie SH. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999; 43: 1866-1869.
39. Mariam DH, Mengistu Y, Hoffner SE, Andersson DI. Effect of RPOB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004; 48: 1289-1294.
40. Bottger EC, Springer B, Pletschette M, Sander P. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat Med 1998; 4: 1343-1344.
41. Sander P, Springer B, Prammananan T et al. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 2002; 46: 1204-1211.
42. Bottger EC, Springer B. Tuberculosis: drug resistance, fitness, and strategies for global control. Eur J Pediatr 2007; 167: 141-148.
43. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010; 8: 260-271.
44. Weinreich DM, Watson RA, Chao L. Perspective: sign epistasis and genetic constraint on evolutionary trajectories. Evolution 2005; 59: 1165-1174.
45. Cohan FM, King EC, Zawadzki P. Amelioration of the deleterious pleiotropic effects of an adaptive mutation in Bacillus subtilis. Evolution 1994; 48: 81-95.
46. Luo N, Pereira S, Sahin O et al. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc Natl Acad Sci U S A 2005; 102: 541-546.
47. Trindade S, Sousa A, Xavier KB, Dionisio F, Ferreira MG, Gordo I. Positive epistasis drives the acquisition of multidrug resistance. PLoS genet 2009; 5: e1000578.
48. Zur Wiesch PA, Kouyos R, Engelstadter J, Regoes RR, Bonhoeffer S. Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect Dis 2011; 11: 236-247.
49. Schrag SJ, Perrot V, Levin BR. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc R Soc Lond B Biol Sci 1997; 264: 1287-1291.
50. Shcherbakov D, Akbergenov R, Matt T, Sander P, Andersson DI, Bottger EC. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 2010; 77: 830-840.
51. Ward H, Perron GG, Maclean RC. The cost of multiple drug resistance in Pseudomonas aeruginosa. J Evol Biol 2009; 22: 997-1003.
52. Gagneux S, Burgos MV, DeRiemer K et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog 2006; 2: e61.
53. Homolka S, Meyer CG, Hillemann D et al. Unequal distribution of resistance-conferring mutations among Mycobacterium tuberculosis and Mycobacterium africanum strains from Ghana. Int J Med Microbiol 2010; 300: 489-495.
54. Hazbon MH, Brimacombe M, Bobadilla Del Valle M et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006; 50: 2640-2649.
55. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358: 591-593.
56. Middlebrook G, Cohn ML. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 1953; 118: 297-299.
57. Mitchison DA. Tubercle bacilli resistant to isoniazid: virulence and response to treatment with isoniazid in guinea-pigs. Br Med J 1954; 1: 128-130.
58. Pym AS, Saint-Joanis B, Cole ST. Effect of katg mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 2002; 70: 4955-4960.
59. Cohen T, Becerra MC, Murray MB. Isoniazid resistance and the future of drug-resistant tuberculosis. Microb Drug Resist 2004; 10: 280-285.
60. Hazbon MH, Bobadilla del Valle M, Guerrero MI et al. Role of EmbB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother 2005; 49: 3794-3802.
61. Sherman DR, Mdluli K, Hickey MJ et al. Compensatory AhpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996; 272: 1641-1643.